Loading...
CureVac Community
NasdaqGM:CVAC Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 25 Fair Values set on narratives written by author
Community Investing Ideas
GSK Milestones And Tech Focus Will Shape Oncology Amid Risks
Key Takeaways Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement. Strong intellectual property, promising GSK licensing agreements, and a solid cash position bolster competitive edge and future revenue prospects.Read more
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
US$5.35
2.7% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-33.07% p.a.
Profit Margin
10.54%
Future PE
88.34x
Price in 2028
US$7.44
